Biopharmaceutical - Immuno-oncology & Cancer Therapeutics
Strategic Profile
Arcus focuses on the ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment, to create and optimize differentiated small-molecule immuno-oncology product candidates. The company's main offerings include development of potential cancer therapies, with particular emphasis on creating combination treatments. 2026 company priorities include rapid enrollment in the PEAK-1 Phase 3 study and initiating a first-line Phase 3 trial in kidney cancer.
Cyborg Score Rationale
The company has a robust pipeline with multiple clinical-stage candidates including Domvanalimab (Phase 2/3) and Quemliclustat (Phase 3) in advanced development. Strong financial position with a debt-to-equity ratio of 0.08 and current ratio of 5.24.
Top Insights
Market cap of approximately $2.52B with trailing 12-month revenue of $240M as of Q3 2025.
Strategic collaborations with AstraZeneca for Phase 3 trials (PACIFIC-8) evaluating domvanalimab in combination with durvalumab.
CEO Terry Rosen recognized among The 100 Most Influential CEOs in Oncology in 2025 for leadership in cancer therapies development.
Clinical-stage company approaching key inflection point with multiple Phase 3 programs and pharma partnerships validating approach.
Named Competitors
Immuno-oncology programs — Cell therapy and personalized neoantigen approaches
Therapeutic pipeline — Diversified biopharmaceutical development
Cell therapy approach — TIL cell therapy for solid tumors
Recent Developments
(Feb 2026) Q4 2025 earnings released with company priorities for 2026 highlighted
(Dec 2025) General Counsel insider activity with sale transaction at $22.16 per share
(2025) CEO recognition among most influential oncology industry leaders
Open the full interactive Arcus Biosciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.